Compare CART & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CART | HALO |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.8B |
| IPO Year | 2023 | 2001 |
| Metric | CART | HALO |
|---|---|---|
| Price | $37.78 | $63.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 11 |
| Target Price | $52.29 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 5.2M | 1.8M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.27 | N/A |
| EPS | 1.60 | ★ 2.56 |
| Revenue | ★ $3,742,000,000.00 | $151,862,000.00 |
| Revenue This Year | $13.31 | $28.24 |
| Revenue Next Year | $9.46 | $12.79 |
| P/E Ratio | ★ $23.59 | $24.83 |
| Revenue Growth | ★ 10.78 | N/A |
| 52 Week Low | $32.73 | $47.50 |
| 52 Week High | $53.50 | $82.22 |
| Indicator | CART | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 29.08 |
| Support Level | $35.28 | $61.23 |
| Resistance Level | $40.15 | $65.40 |
| Average True Range (ATR) | 1.35 | 1.87 |
| MACD | 0.23 | -0.72 |
| Stochastic Oscillator | 56.11 | 6.14 |
Maplebear (Instacart) is a grocery-focused delivery marketplace that connects national and regional grocers with consumers and couriers, and consumers with their favorite stores. Its app provides on-demand convenience for consumers, allows couriers to earn income, and helps grocers to scale their business through digital channels. The marketplace gathers valuable consumer behavior data, attracting consumer-packaged-goods advertisers that seek to reach consumers at the point of purchase. With approximately 600,000 shoppers and 1,800 retail partners, Instacart delivers to about 98% of households in the United States and Canada.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.